MedTrace Logo

gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas

NCT02444000 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-01-23

No results posted yet for this study

Summary

Patients with 1p/19q-codeleted anaplastic gliomas treated with RT + PCV are at risk of neurocognitive deterioration. Treating these patients with PCV alone (could reduce the risk of neurocognitive deterioration without impairing overall survival.

Conditions

  • Anaplastic Gliomas With 1p/19q Codeletion

Interventions

DRUG

PCV chemotherapy alone

PCV cycles are 6 weeks long PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally

DRUG

Radiotherapy+PCV chemotherapy

Radiotherapy followed by 6 cycles of PCV

Sponsors & Collaborators

  • Association de Neuro-Oncologues d'Expression Francaise

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Caroline DEHAIS, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-22
Primary Completion
2022-10-11
Completion
2024-09-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444000 on ClinicalTrials.gov